What are the indications, dosing regimen, contraindications, adverse effects, and counseling considerations for flibanserin in premenopausal women with acquired generalized hypoactive sexual desire disorder?

Flibanserin for Hypoactive Sexual Desire Disorder

Flibanserin is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) and should be dosed at 100 mg orally once daily at bedtime, but carries significant contraindications including alcohol use, moderate/strong CYP3A4 inhibitors, and hepatic impairment that must be strictly observed to prevent severe hypotension and syncope. 1

Indication

Flibanserin is indicated specifically for premenopausal women with acquired, generalized HSDD characterized by:

• Low sexual desire causing marked distress or interpersonal difficulty
• NOT attributable to:
  • Co-existing medical or psychiatric conditions
  • Relationship problems
  • Effects of medications or substances

Key limitations: Not indicated for postmenopausal women, men, or to enhance sexual performance 1

The ASCO guideline supports offering flibanserin to premenopausal women with HSDD, though notes it has not been evaluated in women with cancer history or those on endocrine therapy 2

Dosing Regimen

100 mg orally once daily at bedtime 1

Critical timing requirement: Must be taken at bedtime because daytime administration significantly increases risks of hypotension, syncope, accidental injury, and CNS depression (somnolence, sedation) 1

Missed dose: Take next dose at bedtime the following day; do not double doses 1

Discontinuation criteria: Stop after 8 weeks if no symptom improvement 1

Absolute Contraindications (Boxed Warning)

1. Alcohol Use

• Wait at least 2 hours after consuming 1-2 standard drinks before taking flibanserin at bedtime
• Skip the dose entirely if consuming ≥3 standard drinks that evening
• After taking flibanserin at bedtime, avoid alcohol until the following day
• Combined use dramatically increases risk of severe hypotension and syncope 1

2. Moderate or Strong CYP3A4 Inhibitors

Absolutely contraindicated due to significantly increased flibanserin concentrations causing severe hypotension and syncope 1

Timing if switching:

• Starting flibanserin after stopping CYP3A4 inhibitor: Wait 2 weeks after last inhibitor dose
• Starting CYP3A4 inhibitor after stopping flibanserin: Wait 2 days after last flibanserin dose 1

3. Hepatic Impairment

Any degree of hepatic impairment is an absolute contraindication due to increased flibanserin concentrations 1

4. Known Hypersensitivity

Including anaphylaxis, angioedema (face/lips/mouth swelling), pruritus, urticaria 1

Adverse Effects

Most common (≥2% incidence): 1

• Dizziness
• Somnolence (most frequent at 11.8%)
• Nausea
• Fatigue (10.3%)
• Insomnia
• Dry mouth

Serious adverse effects:

• Hypotension and syncope (especially with alcohol or CYP3A4 inhibitors)
• CNS depression exacerbated by other CNS depressants 2, 3

Meta-analyses confirm statistically significant increases in dizziness, somnolence, nausea, and fatigue compared to placebo 2

Critical Drug Interactions

Weak CYP3A4 inhibitors (including oral contraceptives): Increase flibanserin exposure and adverse reaction incidence 1

Strong CYP2C19 inhibitors: Increase flibanserin exposure, raising risk of hypotension, syncope, and CNS depression 1

CYP3A4 inducers: Not recommended; substantially reduce flibanserin concentrations 1

Digoxin: Flibanserin increases digoxin concentrations; increase monitoring for digoxin toxicity 1

CYP2C19 poor metabolizers: Have increased flibanserin exposure with higher risk of adverse effects 1

Essential Patient Counseling

Safety Precautions

1. Avoid activities requiring full alertness (driving, operating machinery) until at least 6 hours after each dose and until knowing how flibanserin affects them 1

2. Alcohol restrictions are non-negotiable: Explain the 2-hour waiting period and dose-skipping rules clearly 1

3. Pre-syncope management: If experiencing lightheadedness or dizziness, immediately lie supine and seek medical help if symptoms don't resolve 1

4. Medication review: Screen for all CYP3A4 and CYP2C19 inhibitors, including over-the-counter products 1

Efficacy Expectations

Clinical trials demonstrate statistically significant improvements in:

• Satisfying sexual events
• Sexual desire scores (FSFI desire domain)
• Reduction in sexual distress (FSDS-R scores)
• Overall sexual function 2, 4

However, the ASCO guideline notes the risk/benefit ratio remains uncertain 2

Mechanism

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that decreases serotonin while increasing dopamine and norepinephrine centrally 5, 6

Clinical Context

Biopsychosocial approach recommended: Flibanserin should be part of comprehensive HSDD management that includes screening for modifiable factors, psychosocial/psychosexual counseling, and addressing relationship issues 2, 7. The International Society for the Study of Women's Sexual Health process of care algorithm positions pharmacotherapy after education and modification of contributing factors 7.

Common pitfall: Prescribing without adequate screening for contraindications, particularly alcohol use patterns and concomitant medications. The boxed warning exists because these interactions cause severe, potentially dangerous hypotension and syncope 1.